Detection of Hepatocellular Carcinoma by Positron Emission Tomography With C-Acetate-11 and F-fluorodeoxyglucose-18
18F-Fluorodeoxyglucose-PET (FDG-PET)
+ 11Carbon-Acetate-PET
Adenocarcinoma+8
+ Carcinoma
+ Digestive System Diseases
Diagnostic Study
Summary
Study start date: September 1, 2003
Actual date on which the first participant was enrolled.RATIONALE: Imaging procedures, such as carbon-11 acetate positron emission tomography (PET) and fludeoxyglucose F 18 PET, may improve the ability to detect hepatocellular carcinoma (liver cancer) and allow doctors to plan the most effective treatment. PURPOSE: This clinical trial is studying how well carbon-11 acetate PET and fludeoxyglucose F 18 PET work in detecting cancer in patients with liver cancer.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.31 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Diagnostic Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
INCLUSION: * Biopsy-proved HCC (stage I and II by conventional staging) or one or more of the following in a patient with clinically documented cirrhosis: * AFP \> 200 mg/dL; * A contrast-enhancing tumor mass (\>1 cm) by CT or MRI; or * A tumor mass confirmed by arteriography. * Patient must provide written informed consent and have completed conventional imaging and staging before initiation of PET imaging. EXCLUSION: * Pediatric patients under the age of 18 will be excluded from consideration from this study. * Patients with a known prior malignancy (with the exception of basal cell carcinoma of the skin and carcinoma in situ of the cervix) within 5 years will be excluded from entry into the study. However, patients with a prior HCC thought to have a new primary or recurrent HCC are eligible. * Pregnant and breastfeeding patients. * Patients with poorly controlled diabetes mellitus (fasting blood glucose level \> 200 mg/dL)
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.One single intervention group is designated in this study
This study does not include a placebo group
Treatment Groups
Group I
Study Objectives
Primary Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location